L.J. Altfest & Co’s Emergent Biosolutions EBS Stock Holding History

L.J. Altfest & Co’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,677	Closed	-$240K	–	280
2020 Q4	$240K	Buy	+2,677	New	+$246K	0.06%	226

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

L.J. Altfest & Co's EBS Position: Q1 2021 in Review

L.J. Altfest & Co sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 2,677 shares — an estimated $240K sold.

L.J. Altfest & Co first reported a position in EBS in Q4 2020 and held it in 1 quarter. The position peaked at $240K in Q4 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

L.J. Altfest & Co reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
L.J. Altfest & Co sold 2,677 Emergent Biosolutions shares in Q1 2021, an estimated $240K.
L.J. Altfest & Co first reported a position in Emergent Biosolutions in Q4 2020 and held it in 1 quarter.
L.J. Altfest & Co's Emergent Biosolutions position peaked at $240K in Q4 2020.
340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on L.J. Altfest & Co's 13F filing for Q1 2021, filed 7 May 2021.